PHATHOM PHARMACEUTICAL

Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital

14 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

06 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn

28 Nov 2023 07:00:28 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates

09 Nov 2023 07:00:01 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults

01 Nov 2023 16:00:26 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

30 Oct 2023 07:00:38 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

25 Oct 2023 07:01:03 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD

26 Sep 2023 07:01:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

05 Sep 2023 07:00:01 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application

21 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports Second Quarter 2023 Results

10 Aug 2023 07:01:28 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD

12 Jun 2023 07:01:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

09 Jun 2023 15:01:22 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

01 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock

23 May 2023 18:41:15 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock

23 May 2023 15:01:12 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA

23 May 2023 15:00:40 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports First Quarter 2023 Results

10 May 2023 07:00:01 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023

09 May 2023 07:00:15 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch

04 Apr 2023 07:00:01 By Nasdaq GlobeNewswire